Skip to content
OpenCapital
Get started

Black Diamond Therapeutics, Inc. BDTX Q1 2026 earnings

Reported May 7, 2026 · After market close

EPS-$0.16Beat by $0.02
Revenue estimate$25.0M
EPS estimate-$0.18

Next report

Aug 6, 2026 (In 1 week)
EPS estimate-$0.18

Versus estimates

Revenue

Q1 2025$70.0MBeat by $42.0M

Diluted EPS

Q1 2026-$0.16Beat by $0.02
Q4 2025-$0.14Beat by $0.04Q3 2025-$0.15Beat by $0.07Q2 2025-$0.19Beat by $0.06Q1 2025$0.98Beat by $0.96Q4 2024-$0.28Beat by $0.03

Ask the moment Black Diamond Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Black Diamond Therapeutics, Inc. report Q1 2026 earnings?
Black Diamond Therapeutics, Inc. (BDTX) reported Q1 2026 earnings on May 7, 2026 after market close.
What were Black Diamond Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Black Diamond Therapeutics, Inc. reported eps of $-0.16 for Q1 2026.
Did Black Diamond Therapeutics, Inc. beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.18 by $0.02.
Where can I find Black Diamond Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001701541-26-000015) and the 10-Q periodic report (0001701541-26-000017) directly on SEC EDGAR. The filing index links above go to sec.gov.